Twist Bioscience (TWST) Short-Term Debt to Capital

Twist Bioscience, Inc. - graphic logo of issuer TWST

Current price action for Twist Bioscience (TWST) demonstrates metrics at 0.02, while the business relies on stable demand from scientists for biomaterials, ensuring resilience against market volatility. Expanding silicon plant capacities allows the company to scale the production of synthetic chains. Laboratory efficiency is guaranteed through the digitalization of orders and the rapid transportation of finished genetic products.

Twist Bioscience Corp (TWST): Short-Term Loans to Capital Ratio from 07/04/2022 to 10/29/2026

Analytical breakdowns for twistbioscience.com (TWST)

- price and consensus price forecast:
Price Chart Twist Bio|TWST - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Twist Bioscience Inc|TWST - Enterprise Value
- book capitalization data:
Accounting Value per Share Twist Bioscience|TWST - Total Net Assets|Market Cap to Net Assets Ratio twistbioscience.com|TWST - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Twist Bioscience|TWST - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Twist Bioscience, Inc.|TWST - Company Total Debt Obligations|Debt to Book Value Twist Bioscience Inc|TWST - Amount of Long-Term Liabilities|Company Current Liabilities Twist Bioscience
Fundamental company analysis:TWST, Twist Bio
Finished products of Twist Bioscience, Inc.

Twist Bioscience's leadership in high-precision DNA synthesis requires significant R&D investment, making the management of current liabilities critical. The ratio of short-term borrowings to equity measures the proportion of debt maturing within one year, allowing the short-term debt-to-equity ratio trend to assess liquidity risks and the sustainability of the issuer's financial leverage.

Competitors of Twist Bioscience

Short-Term Debt to Equity Tempus AI TEM|Short-Term Debt to Capital Ratio Qiagen Corp (QGEN)|Short-Term Debt to Capital IONS (Ionis Pharmaceuticals)|RGEN - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Avidity Biosciences, Inc. RNA|CRISPR Therapeutics Inc (CRSP) - Short-Term Loans to Capital Ratio|WGS (Sema4) - Short-Term Debt to Equity Ratio|Ultragenyx Corp (RARE) - Short-Term Debt to Equity Ratio|BEAM: Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient SRPT|TXG (10x Genomics) - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Intellia Therapeutics Inc NTLA|Short-Term Debt to Equity Ratio Stoke (STOK)|BLFS - Short-Term Loans to Capital Ratio|Short-Term Debt to Equity Ratio Wave Life Sciences (WVE)|MAZE - Ratio of Short-Term Indebtedness to Capital|Sionna Therapeutics (SION) - Short-Term Debt to Capital|Prime Medicine Inc (PRME) - Short-Term Debt to Equity|TSHA: Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient QURE|MeiraGTx Holdings plc - Short-Term Debt to Equity|Current Liabilities to Capital RGNX (regenxbio.com)|Short-Term Debt to Equity SLDB|Short-Term Debt to Capital Coefficient Ocugen Inc OCGN|PACB: Short-Term Debt to Capital|BNTC - Short-Term Debt to Equity Ratio|Design Therapeutics - Short-Term Debt to Capital|rocketpharma.com (RCKT) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital FDMT (4D Molecular Therapeutics, Inc.)|Current Liabilities to Capital LXEO|Short-Term Debt to Equity Korro Bio, Inc. KRRO|Short-Term Debt to Capital Ratio Editas Corp (EDIT)|Silence Therapeutics - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio ProQR PRQR|CDXS (Codexis Bio) - Short-Term Debt to Capital|Sangamo Therapeutics Inc. (SGMO) - Current Liabilities to Capital|NAUT - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Metagenomi Therapeutics|Short-Term Debt to Equity Ratio DTIL|Short-Term Debt to Equity Ratio GBIO|BOLD (Boundless Bio) - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient exicuretx.com XCUR|Short-Term Debt to Equity Ratio Imunon (IMNN)|Short-Term Loans to Capital Ratio Phio Pharmaceuticals Corp PHIO|Mustang Bio Corp (MBIO) - Short-Term Debt to Capital|RNAZ: Short-Term Debt to Capital Ratio|Short-Term Debt to Equity bionanogenomics.com|Applied DNA Sciences Inc (APDN) - Short-Term Debt to Capital Ratio|BLUE (Bluebird Bio) - Short-Term Debt to Capital|Short-Term Debt to Capital ImmunoPrecise (IPA)|Short-Term Debt to Equity Ratio Omega Therapeutics|Short-Term Loans to Capital Ratio singulargenomics.com OMIC|Regulus Therapeutics Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Syros Pharmaceuticals Inc. SYRS|Short-Term Debt to Capital TBIO (Codex DNA)|TCON: Short-Term Debt to Capital Coefficient|Unity Biotechnology - Short-Term Debt to Equity